IDIA.SW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 05:54):

Stats
Today's Volume	323 200
Average Volume	1.15M
Market Cap	396.72M
EPS	CHF0 ( 2024-02-05 )
Next earnings date	( CHF-0.810 ) 2024-05-20
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-0.910
ATR14	CHF0.0110 (0.57%)

Volume Correlation

Long: 0.00 (neutral)

Short: -0.13 (neutral)

Signal:(64.588) Neutral

Idorsia Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Idorsia Ltd Correlation - Currency/Commodity

-0.32
( neutral )

0.41
( neutral )

0.00
( neutral )

-0.29
( neutral )

0.02
( neutral )

0.79
( moderate )

Idorsia Ltd Financials

Annual	2023
Revenue:	CHF0
Gross Profit:	CHF0 (0.00 %)
EPS:	CHF0

FY	2023
Revenue:	CHF0
Gross Profit:	CHF0 (0.00 %)
EPS:	CHF0

FY	2022
Revenue:	CHF97.10M
Gross Profit:	CHF90.84M (93.55 %)
EPS:	CHF-4.67

FY	2021
Revenue:	CHF35.35M
Gross Profit:	CHF0.00 (0.00 %)
EPS:	CHF-3.77

Financial Reports:

No articles found.

Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.